Abstract
Liver kinase B1 (LKB1; also known as STK11) is a serine/threonine kinase and tumour suppressor that is mutated in Peutz-Jeghers syndrome (PJS), a premalignant syndrome associated with the development of gastrointestinal polyps. Proglucagon-expressing enteroendocrine cells are involved in the control of glucose homeostasis and the regulation of appetite through the secretion of gut hormones such as glucagon-like peptide-1 (GLP-1) and peptide tyrosine tyrosine (PYY) (incretins). To determine the role of LKB1 in these cells, we bred mice bearing floxed alleles of Lkb1 against animals carrying Cre recombinase under proglucagon promoter control. These mice (GluLKB1KO) were viable and displayed near-normal growth rates and glucose homeostasis. However, they developed large polyps at the gastro-duodenal junction, and displayed premature mortality (death from 120 days of age). Histological analysis of the polyps demonstrated that they had a PJS-like appearance with an arborising smooth-muscle core. Circulating GLP-1 levels were normal in GluLKB1KO mice and the polyps expressed low levels of the peptide, similar to levels in the neighbouring duodenum. Lineage tracing using a Rosa26tdRFP transgene revealed, unexpectedly, that enterocytes within the polyps were derived from non-proglucagon-expressing precursors, whereas connective tissue was largely derived from proglucagon-expressing precursors. Developmental studies in wild-type mice suggested that a subpopulation of proglucagon-expressing cells undergo epithelial-mesenchymal transition (EMT) to become smooth-muscle-like cells. Thus, it is likely that polyps in the GluLKB1KO mice developed from a unique population of smooth-muscle-like cells derived from a proglucagon-expressing precursor. The loss of LKB1 within this subpopulation seems to be sufficient to drive tumorigenesis.
- Received November 1, 2013.
- Accepted September 3, 2014.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
Article navigation
Related articles
Cited by...
More in this TOC section
Similar articles
Other journals from The Company of Biologists
Minifocus – Gene-edited zebrafish models take disease research to the next level
The potent combination of CRISPR/Cas9 and zebrafish as a model organism offers enormous potential for research into human diseases caused by point mutations. Three new articles published in DMM from the labs of Lisa Maves, Jeroen Bakkers and Andy Willaert use zebrafish to explore how advances in CRISPR/Cas9 optimisation offer a new level of accuracy and specificity previously out of reach for research into this type of human genetic disorder. A new Editorial by Sergey Prykhozhij and Jason Berman examines the implications of these articles in the progression of zebrafish knock-in models, the advantages and challenges of working with such precise mutants, and the translational relevance of these models for human disease research.
At a glance – Immune regulation of metastasis: mechanistic insights and therapeutic opportunities
In a new Review and accompanying poster, Olga S. Blomberg, Lorenzo Spagnuolo and Karin E. de Visser discuss the dual role of the immune system in metastasis and summarize promising therapeutic strategies to target tumor-immune interactions.
Editor's choice – Apolipoprotein E deficiency accelerates atherosclerosis development in miniature pigs
In our newest Editor's choice article, Yifan Dai and colleagues describe an ApoE knockout minipig model that displayed severe hypercholesterolemia and spontaneously developed human-like atherosclerotic lesions in the aorta and coronary arteries within 6 months of feeding on a high-fat and high-cholesterol diet.
First Person interviews
Have you seen our interviews with the early-career first authors of our papers? Recently, we caught up with first authors Annekatrien Boel and Georgina Askeland.
Journal meeting – Blood disorders: models, mechanisms and therapies
Register your interest in our upcoming meeting on blood disorders and their treatment, organised by DMM Editor-in-Chief Monica Justice, Nancy Speck, Paresh Vyas and Leonard Zon. The meeting will bring together diverse front-line researchers, stimulating discussions across basic research and clinical disciplines, and fostering collaborative links among researchers.
Why should you publish your next paper in DMM?
DMM aims to promote human health by encouraging collaboration between basic and clinical researchers, covering a diverse range of diseases, approaches and models. Our Editors are all active researchers in the field – your peers, colleagues and mentors, who know how much work has gone into every paper. Recently, we have introduced format-free submission, and we accept peer review reports from other journals, making submission as easy as possible for our authors. Send us your next great paper – publish with us and you'll be in good company.
preLights – Switching melanoma behaviour with STAT3
Hannah Brunsdon highlights a recent preprint from Richard Moriggl and colleagues showing that STAT3 represses the MITF pathway to drive metastasis in melanoma. The preprint also emphasises that there are huge challenges ahead in correctly balancing and timing drug treatment to prevent unwanted activation of genes which can exert large effects on tumour growth and survival.
Back in July, Hannah also highlighted the preprint from the Maves lab that is now published in DMM and features in our minifocus on CRISPR-generated zebrafish models.
Catch up with recent preLights selected for the translational biology community in our latest Table of Contents.